Navigation Links
Uroplasty on Preliminary List of Additions to Russell 3000® and Russell Global® Indexes
Date:6/13/2011

MINNEAPOLIS, June 13, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced it has been included on a list of preliminary additions to the Russell 3000® Index and the Russell Global® Index posted by Russell Investments on June 10, 2011 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 24, 2011.  

"The preliminary addition of Uroplasty to the Russell 3000 and Russell Global indexes is a testament to the progress we have made in building valuation," said David Kaysen, president and CEO of Uroplasty.  "It should help expand awareness of our company, especially among institutional investors, as we continue to execute our growth strategy for our Urgent PC® and Macroplastique® product lines."

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell Global Index measures the performance of the global equity market based on all investable equity securities, and includes approximately 10,000 securities in 48 countries and covers 98% of the investable global market. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies.  The indexes are reconstituted annually.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140


EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820

Chris Gale (Media), 646.201.5431




'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplastys Dave Kaysen to Ring NASDAQ Closing Bell
2. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
3. Uroplasty to Present at the JMP Securities Research Conference
4. Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
5. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
6. Uroplasty to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
7. Uroplasty Reports Financial Results for the Third Quarter FY2011
8. Uroplasty to Issue Third Quarter 2011 Results on January 27, 2011
9. Uroplasty Announces Addition of Robert Kill to its Board of Directors
10. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
11. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
(Date:5/3/2016)... 4, 2016 Research and Markets ... Stem Cell Therapy Market Outlook 2020" report to ... ) , ,Recombinant technology has improved significantly in past ... be developed in coming years. Many cancer drugs have ... cell therapies are also expected to be developed with ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/5/2016)... PA (PRWEB) , ... May 05, 2016 , ... ... on long-acting injectables (LAIs), today announced a development collaboration with the ... to treat serious mental disorders such as schizophrenia. , LAI medicines can offer ...
(Date:5/5/2016)... Palm Beach, Fla. (PRWEB) , ... May 05, 2016 , ... ... Vision Institute in San Diego, California. The laser eye center will now be called ... recognized surgeons and attentive staff will remain at the full-service facility to ensure that ...
(Date:5/5/2016)... ... May 05, 2016 , ... LELO has discovered many people ... fans reach out via email, social media and on the Volonté blog seeking advice ... way I masturbate ‘normal’ or ‘correct’?” , While some methods are more common than ...
(Date:5/5/2016)... Fort Collins, CO (PRWEB) , ... May 05, ... ... has announced the commencement of a master charity program created to assist the ... every 60 days, working closely with nonprofit organizations and community leaders. Their hope ...
(Date:5/5/2016)... TX (PRWEB) , ... May 05, 2016 , ... Vitenas ... AIA/AAH Healthcare Design Awards, presented by the American Institute of Architects and the Academy ... designed by the renowned Perkins+Will and Harrell Architects, opened to patients in October of ...
Breaking Medicine News(10 mins):